Yunyun Zhou

Eli Lilly (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index1.9kcitations103works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

MicroRNA in disease regulation(22), Lung Cancer Treatments and Mutations(12), RNA modifications and cancer(12), Biomedical Text Mining and Ontologies(10), Cancer-related molecular mechanisms research(9)

Publications103 total

Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01
Journal of Thoracic Oncology·2025
Safety and Efficacy of Bridging Radiation Therapy for Refractory/Relapsed Diffused Large B-cell Lymphoma: Systematic Review and Meta-Analysis
International Journal of Radiation Oncology*Biology*Physics·2025Open Access
Diagnosis and Treatment of Primary Tracheobronchial Tumors
Cancer Medicine·2025Open Access
Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy
JTO Clinical and Research Reports·2024· 2 citedOpen Access
P2.11A.05 The Impact of Tumor Molecular Features and Smoking History on Survival with Chemo-Immunotherapy in EGFR-Mutant NSCLC
Journal of Thoracic Oncology·2024Open Access
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels
Lung Cancer·2024· 19 citedOpen Access
Enhancing phenotype recognition in clinical notes using large language models: PhenoBCBERT and PhenoGPT
Patterns·2023· 55 citedOpen Access
Trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer growth and immune suppression via phospholipid scramblase anoctamin 6 (ANO6)
2023· 15 citedOpen Access
Correction: Model performance and interpretability of semi-supervised generative adversarial networks to predict oncogenic variants with unlabeled data
BMC Bioinformatics·2023Open Access
Transformer‐based DNA methylation detection on ionic signals from Oxford Nanopore sequencing data
Quantitative Biology·2023· 3 citedOpen Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2023Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Yang Xie(13), Junqing Wang(8), Kai Wang(7), Adi F. Gazdar(6), John D. Minna(6), Guanghua Xiao(6), Luc Girard(5), Yin‐Yuan Mo(5), Keli Xu(5), John V. Heymach(4), Lin Yang(4), Guanghua Xiao(4), Marilyn M. Li(4), Kai Wang(4), Xiaochun Fei(4), Xuehua Chen(4), Jacqueline Peng(4), David A. Boothman(3), Ignacio I. Wistuba(3), Hao Tang(3)